Who are Monovalent Tetanus vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tetanus-diphteria, Td alone, tetanus diphtheria toxoids vaccine, DT, Td, Tetanus and Diphtheria Toxoids Adsorbed.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/monovalent-tetanus-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Monovalent Tetanus vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monovalent Tetanus vaccine (Monovalent Tetanus vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Toxoid vaccine. Area: Immunology / Infectious Disease.

phase 3 Toxoid vaccine Tetanus toxin (tetanospasmin) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Monovalent Tetanus vaccine (Monovalent Tetanus vaccine) — Sanofi Pasteur, a Sanofi Company. A monovalent tetanus toxoid vaccine that stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against Clostridium tetani infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Monovalent Tetanus vaccine TARGET	Monovalent Tetanus vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Toxoid vaccine	Tetanus toxin (tetanospasmin)
Tetanus-diphteria	Tetanus-diphteria	Hospital Clinic of Barcelona	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin
Td alone	Td alone	Korea University Guro Hospital	marketed	Toxoid vaccine	Tetanus toxin and diphtheria toxin
tetanus diphtheria toxoids vaccine	tetanus diphtheria toxoids vaccine	Biogen	marketed	Toxoid vaccine
DT	DT	Hoffmann-La Roche	marketed	Toxoid vaccine	Diphtheria toxin and tetanus toxin
Td	Td	University of Florida	marketed	Toxoid vaccine	Tetanus toxin (tetanospasmin) and diphtheria toxin
Tetanus and Diphtheria Toxoids Adsorbed	Tetanus and Diphtheria Toxoids Adsorbed	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Toxoid vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Toxoid vaccine class)

GlaxoSmithKline · 2 drugs in this class
Genentech, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Hospital Clinic of Barcelona · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Nationwide Children's Hospital · 1 drug in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class
Sinovac Life Sciences Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Monovalent Tetanus vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/monovalent-tetanus-vaccine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab